AUTHORS
Laura Rolke, PhD, MPH, Danielle Boselli, MS2, Jing Ai, MD, PhD3, Brittany Knick Ragon, MD4, Aleksander Chojecki, MD5, Nilay Shah, MD6, Srinivasa Reddy Sanikommu, MD7, Kelly Brook Weaver, DNP, APRN, ACNS-BC, NP-C, OCN, AOCNP8, Lawrence J Druhan, PhD9, Michael R. Grunwald, MD10, Thomas G Knight, MD11
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
3 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
4 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
6 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
9 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
10 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
11 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
ABSTRACT
Introduction: Curative therapy for adults with acute myeloid leukemia (AML) often depends on successful delivery of intensive, high-risk treatments including induction chemotherapy followed by consolidation with high dose cytarabine (HiDAC) and/or allogeneic hematopoietic stem cell transplantation (HSCT). These features may make AML outcomes particularly sensitive to community-level barriers related to socioeconomic status, access to resources, housing, and transportation. We evaluated whether county-level social vulnerability, measured by the Social Vulnerability Index (SVI), was associated with 5-year overall survival (OS) and cancer-specific survival (CSS) for adults with AML aged 18 to 60 years, an age range in which intensive and HSCT-based treatment strategies are commonly considered.
Methods: We identified adult patients aged 18 to 60 years diagnosed with AML (Site recode ICD-O-3/WHO 2008 definition) from 2003 to 2017 in the National Cancer Institute’s SEER 17 Research Plus Incidence Database with state and county FIPS codes. Patients with mixed-phenotype acute leukemia (MPAL) diagnosis, diagnosis at death or autopsy, or incomplete survival data (including alive with no survival time) were excluded. County of residence at diagnosis was linked to the Centers for Disease Control and Prevention’s 2014 national SVI rankings and categorized into quintiles from least vulnerable (Q1) to most vulnerable (Q5). We estimated 5-year overall (OS) and cancer-specific survival (CSS) across SVI quintiles and subthemes using Kaplan-Meier methods and Cox proportional hazards models. Covariates include age group, sex, race/ethnicity, first versus subsequent primary cancer status, diagnosis time group, and US Census Region.
Results: The cohort included 13,163 patients with AML. The mean age was 45.9 years. 6,886 (52.3%) were male, 7,890 (60.0%) were non-Hispanic (NH) White, 1,478 (11.2%) were non-Hispanic Black, 2,387 (18.1%) were Hispanic, 7,400 (56.2%) resided in the West census region, and 10,702 (81.3%) had AML as their primary cancer. Patients were distributed across SVI quintiles as follows: Q1 (n=903, 6.9%), Q2 (n=1,997, 15.2%), Q3 (n=4,243, 32.2%), Q4 (n=3,538, 26.9%), Q5 (n=2,480, 18.4%).
Five-year OS declined stepwise with increasing county-level social vulnerability: Q1 = 40.3%, Q2 = 38.8%, Q3 = 35.9%, Q4 = 33.1%, and Q5 = 31.5%. Five-year CSS showed a similar gradient, declining from 44.8% in Q1 to 37.0% in Q5. In the adjusted cox proportional hazards model for 5-year OS, higher SVI remained associated with inferior OS compared to Q1, including Q3 (HR=1.13; 95% CI: 1.02-1.24; p<0.05), Q4 (HR=1.18; 95% CI 1.06-1.30; p<0.01), and Q5 (HR=1.27; 95% CI 1.14-1.41; p<0.001). Of the covariates, NH Black race, Hispanic ethnicity, older age (40 to 49; 50 to 60), secondary AML diagnosis, southeast census region, and west census region were independently associated with higher risk of death. Decreased risk of death was associated with female sex and more recent diagnosis period (2008 to 2012; 2013 to 2017).
SVI can also be analyzed from four subthemes that make up the total score. Among SVI subthemes, socioeconomic status (HR 1.29; 95% CI: 1.19-1.39; p<0.001), household composition (HR 1.17; 95% CI: 1.06-1.28; p<0.01), and housing type and transportation (HR 1.13; 95% CI: 1.03-1.24; p<0.01) were independently associated with increased overall mortality risk in the highest versus lowest quintile.
Conclusions: County-level social vulnerability was independently associated with inferior 5-year OS and CSS in adults aged 18 to 60 years with AML. The survival disparity between the least and most vulnerable counties was clinically meaningful, with an 8.8% absolute difference in 5-year OS, a 27% higher overall mortality risk, and a 22% higher risk of cancer-specific mortality. These disparities persist after accounting for additional demographic and clinical factors. These findings support SVI as a population-level risk marker for AML outcomes and may identify patients and regions at risk for worse outcomes along the curative-intent AML treatment pathway. Prospective studies should evaluate whether early financial navigation, transportation support, care coordination, and interventions to improve access to intensive therapy and HSCT can mitigate these disparities.
DISCLOSURES
Thomas G Knight, MD: No relevant conflicts of interest to declare.